Sol-Gel Technologies (SLGL) Net Income towards Common Stockholders (2017 - 2026)
Sol-Gel Technologies (SLGL) posted quarterly Net Income towards Common Stockholders of $3.7 million for Q1 2026, down 57.69% year-over-year from $8.8 million in Q1 2025, and up 106.02% quarter-over-quarter from -$61.9 million in Q4 2025.
Analysis
Sol-Gel Technologies (SLGL) Net Income towards Common Stockholders (2017 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Net Income towards Common Stockholders for 10 consecutive years, with $3.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 57.69% year-over-year to $3.7 million; the TTM figure through Mar 2026 stood at -$64.5 million (down 34.58% YoY), while the FY2025 annual figure was -$66.0 million, down 6.86% from the prior year.
- Net Income towards Common Stockholders advanced to $3.7 million in Q1 2026 per SLGL's latest filing, from -$61.9 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $10.7 million in Q1 2023 and bottomed at -$61.9 million in Q4 2025.
- Historically, Net Income towards Common Stockholders has averaged -$8.8 million across 5 years, with a median of $0.01 in 2022.
- On a YoY basis, Net Income towards Common Stockholders climbed as much as 2100.0% in 2023 and fell as far as 21327599900.0% in 2023.
- Sol-Gel Technologies' Net Income towards Common Stockholders stood at -$0.25 in 2022, then tumbled by 21327599900.0% to -$53.3 million in 2023, then declined by 4.82% to -$55.9 million in 2024, then fell by 10.78% to -$61.9 million in 2025, then surged by 106.02% to $3.7 million in 2026.
- Business Quant data shows SLGL's Net Income towards Common Stockholders at $3.7 million in Q1 2026, -$61.9 million in Q4 2025, and -$6.3 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Sol-Gel Technologies | 194.01 Mn | 146.08 Mn | - | -4.64 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -4.64 Mn |
| Mar 31, 2026 | 3.86 Mn |
| Dec 31, 2025 | -3.41 Mn |
| Sep 30, 2025 | -6.29 Mn |
| Jun 30, 2025 | 10.85 Mn |
| Mar 31, 2025 | 9.07 Mn |
| Dec 31, 2024 | -6.10 Mn |
| Sep 30, 2024 | -828,000.00 |
| Jun 30, 2024 | 1.27 Mn |
| Mar 31, 2024 | 6.71 Mn |
| Dec 31, 2023 | -5.41 Mn |
| Sep 30, 2023 | -6.31 Mn |
| Jun 30, 2023 | -7.08 Mn |
| Mar 31, 2023 | 11.06 Mn |
| Dec 31, 2022 | -6.21 Mn |
| Sep 30, 2022 | -3.63 Mn |
| Jun 30, 2022 | 134,000.00 |
| Mar 31, 2022 | 5.95 Mn |
| Dec 31, 2021 | 13.96 Mn |
| Sep 30, 2021 | 1.27 Mn |